Xavier Forns
Jefe de la UnidadGrupo de investigación
- Enfermedades hepáticas víricas, genéticas e inmuno-mediadas Group leader (R4)
Publicaciones destacadas
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Autores:Referencia: Journal Of Hepatology 2019. -
Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
Autores:Referencia: Journal Of Viral Hepatitis 2018. -
Shorter HBIG administration is not associated to HBV recurrence when receiving combined prophylaxis after liver transplantation.
Autores:Referencia: Liver International 2018. -
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Autores:Referencia: Hepatology 2018. -
Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.
Autores:Referencia: Journal Of Hepatology 2018. -
Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure.
Autores:Referencia: Gastroenterology 2018. -
The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition
Autores:Referencia: Journal Of Hepatology 2018. -
Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
Autores:Referencia: Gastroenterology 2017. -
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Autores:Referencia: Lancet Infectious Diseases 2017. -
EASL Recommendations on Treatment of Hepatitis C 2016
Autores:Referencia: Journal Of Hepatology 2017.
Proyectos destacados
-
Estudio de la disfunción de la respuesta inmune adaptativa periférica e intrahepática en las diferentes fases de la hepatitis crónica por el virus de la hepatitis B
Investigador/a principal: Xavier Forns BernhardtFinanciador: Instituto de Salud Carlos IIICódigo: PI18/00079Duración: 01/01/2019 - 01/01/2022 -
Evaluación prospectiva de un modelo externalizado de consulta especializada con intervención educacional para reducir la reinfección por el virus de la hepatitis C en un centro de reducción de daños
Investigador/a principal: Xavier Forns BernhardtCódigo: 2020I018Duración: 01/01/2021 - 31/12/2022 -
TherVacB: A therapeutic vaccine to cure hepatitis B
Investigador/a principal: Xavier Forns BernhardtCódigo: 848223Duración: 01/01/2020 - 31/12/2024 -
Defining the best strategy for global HCV screening, linkage-to-care, education and prevention in PWID population and validation of a new diagnostic dried blood spot test
Investigador/a principal: Sabela Lens GarcíaCódigo: IN-ES-987-5349Duración: 02/05/2018 - 31/03/2022